While our study did not include in vivo validation, this reflects the recognized limitations of current animal models for COVID-19, which often require humanized ACE2 expression and still fall short of recapitulating the full spectrum of human immune responses and disease severity [80]. The gene discussed is ACE2; the disease is COVID-19.